Although several clinical trials targeting the main components of AD neuropathology, such as amyloid-beta (Aβ) peptide and phosphorylated Tau (pTau) protein have failed to achieve good outcomes (Mehta et al., 2017; Mullane and Williams, 2018; Yiannopoulou et al., 2019), it is believed that the heterogeneous nature of the disease mechanism among patients with AD determines the response to the drug (Devi and Scheltens, 2018). The gene discussed is MAPT; the disease is Alzheimer disease.